Abstract
The role of metformin in the treatment of gestational diabetes (GD) remains controversial. It has long been used in clinical trials, and there is now sufficient data on the absence of teratogenic effects of the medication and its high safety profile. This has allowed metformin to be included as a second- or even first-line therapy in many updated international guidelines in recent years. However, in Russia, the use of metformin in pregnant women with GD is still not recommended, according to the approved clinical guidelines for the treatment of GD in 2024. At the same time, the Federal Service for Supervision of Healthcare of the Russian Federation has updated the instructions for the medical use of metformin and removed “pregnancy” from the “Contraindications” section. It also states that metformin can be used in cases of extreme necessity, when the expected benefit of therapy for the mother outweighs the possible risk to the fetus. This literature review analyzes data on the advantages and disadvantages of metformin in GD and proposes criteria for selecting candidates for this therapy in further studies. Key words: metformin, gestational diabetes (GD), pregnancy